Sarcoma and Conventional Flow Cleanroom

recertification of drugs: cap. Indications for use drugs: h.limfoblastnyy leukemia in children and adults, Non-Hodgkin's lymphoma recertification children. Side effects of the use of drugs: most cases side effects are mild and transient, with no special care required for their removal; severe congestive heart failure include, MI, cardiomyopathy, cardiomegaly, complete heart block, atrial fibrillation, stroke, pericarditis, infiltrates in the lungs Glutamic-oxalacetic Transaminase pulmonary hypertension, pancreatitis, gastritis, ulcer duodenum, convulsive seizures, headache, feeling the heartbeat, diarrhea, Chronic Renal Failure nausea, vomiting, abdominal pain, dizziness, fever, recertification back pain, rash, itching, flu-like symptoms, chills, photosensitization, arrhythmia, Intravascular Ultrasound hypertension, thrombosis, angina, heart failure, vasodilation, orthostatic hypotension, headache, anemia, thrombocytopenia, hemorrhage, lymphadenopathy, arthralgia, myalgia, arthritis, bone pain, depression, drowsiness, recertification hypertension, nervousness, amnesia, loss or weight gain, edema, rhinitis, nasal bleeding, sinusitis, pneumonia, bronchitis, sweating, skin diseases, amblyopia, blurred vision Intravenous Urogram hearing, conjunctivitis, visual fields abnormalities, tinnitus, infection urinary tract, hematuria, dysuria, nokturiya, urinary incontinence. Pharmacotherapeutic group: L01XX35 - Antineoplastic other means. 50 mg № 50. The main effect of pharmaco-therapeutic effects of drugs: systemic retinoids, inducer of recertification differentiation., Induces differentiation and inhibits proliferation of transformed cells of hematopoiesis, including at miyeloleykozi in humans, the mechanism of action of G promiyelotsytarnomu leukemia (HPML) is to change the link transretynoyevoyi acid nuclear retinoic acid receptors (RRB), and a-retinoic acid receptor also changes due to merger with protein PML. Contraindications to the use of drugs: City, life-threatening complication of thrombocytosis, severe degree of liver failure. Dosing and drug dose: initial dose 0.5 mg 4 g / day or 1.0 mg of 2 g / day dose of this support within one week, Sudden Infant Death Syndrome dose should be brought to the minimally effective, which will be sufficient to maintain a platelet count below the level 600 thousand / ml, and ideally - to recertification levels, increasing the dose should not exceed 0.5 mg per day during the week, the daily dose is 10 mg, and one-shot - 2,5 mg of the optimal dose of platelets starts to decrease because of 7-14 days, complete response (platelets <600 thousand / ml) comes in 4-12 weeks, usually at a dose of 1,5-3,0 mg / day, as data on the optimal initial dose in children limited, to be recertification the initial dose 0.5 mg / day; selection minimally effective and maintenance doses in children and adults are no different, with an average degree of liver failure treatment recommended starting dose of 0.5 mg / day, which must maintain at least a week under close supervision as the SS system to increase the dose by more than 0.5 mg per week should not be. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, simultaneous reception of tetracyclines, mini piley of progesterone and vitamin A. Method of production of drugs: cap. Method of production of drugs: cap.